



ten23 health expands sterile manufacturing capacity at its VIVA 1[®] facility through completion of its first expansion and the introduction of an additional shift

Basel, 4th of September 2023. ten23 health[®], a global contract development and manufacturing organization, today announced a capacity expansion for the manufacture of sterile drug product at its Visp facility. This will help to meet rapidly increasing customer demand.

With customer demand for sterile fill & finish services increasing, ten23 health is expanding the available capacity at its VIVA 1[®], Visp Valais (Switzerland) sterile manufacturing facility.

The capacity increase of storage space and visual inspection capabilities has previously been announced (19.09.2022 [press release](#)). Following the successful completion of the GMP inspection by Swissmedic and obtaining the related GMP license, the new storage areas becomes operational in September 2023. Now the output of ten23's existing sterile manufacturing facility (Line 1) in Visp will also be gradually increased by a further 50% capacity, by hiring more staff to operate an additional shift.

In addition, as announced previously, further expansions of the overall pharmaceutical development and manufacturing services of ten23 are underway at the Company's BASE[®] (Basel, Switzerland) and VIVA[®] (Visp, Switzerland) facilities to support the industry's growing demand for complex sterile product development, testing and manufacturing. Through VIVA 2[®], ten23 is building two additional filling lines for sterile commercial supplies of ready-to-use syringes, cartridges, and vials (line 2) and liquid or freeze-dried clinical and commercial vial supplies (line 3). The project is on track and a first customer project and tech transfer is signed for manufacturing in 2024 and 2025.

"We are thrilled to offer our customers additional sterile manufacturing capacity for sophisticated and highly precise Drug Product-presentations such as syringes and cartridges, increased capacity until the two new production lines becoming fully operational." said Prof.

Dr. Hanns-Christian Mahler, CEO of ten23 health. *“With recent demand increases for clinical as well as commercial drug launches, our customers are keen to take advantage of increased capacity from the existing VIVA 1® facility, before the new plant VIVA 2® will be utilized for larger scales”*

About ten23 health®

ten23 health®, located in Basel and Visp, Switzerland, is the human-centric and sustainable strategic partner of choice for the pharmaceutical industry and biotech start-ups: we develop, manufacture, and test modern sterile medicines. At our two sites we support our clients in developing, manufacturing and testing differentiated, complex, stable, usable, and safe injectable treatment options for patients.

ten23 health® combines the latest scientific findings with proven and tested world-class industry and regulatory expertise to forge new paths for supporting clients. We provide our innovative services in a fair and sustainable manner, respecting people’s health and the future of our planet. ten23 health is solidly financed through the long-term commitment of 3i Group, an internationally reputable equity partner.

About BASE® and VIVA®

BASE® and VIVA® are our two facilities in Basel and Visp Valais, Switzerland. It stands for our roots in Basel and life and nature in Valais. We have a strong connection to the local region, and we value our roots, life and nature and provide Swiss Quality. At ten23 health we embrace diversity with employees from different nationalities while still cherishing traditions. We are proud to be an employer in Switzerland where we can show our commitment to Patients, People and Planet.

About the company’s name

The numeric value for the number of molecules in a sample of one mol is called Avogadro constant and equals $6.022 \cdot 10^{23}$. Gram quantities of material contain the incredible number of 10^{23} atoms, which was an important discovery to understand the composition of matter: The world is built from small units, and not a homogeneous mass.

About 3i Group

3i is an investment company with two complementary businesses, Private Equity and Infrastructure, specializing in core investment markets in Northern Europe and North America. 3i's Private Equity team provides investment solutions for growing companies, backing entrepreneurs and management teams of mid-market companies with an Enterprise Value typically between €100m - €500m. The company backs international growth plans, providing access to its network and expertise to accelerate the growth of companies across the consumer, industrial, healthcare and business and technology services industries.

Media contacts:

ten23 health: Mara Willa, mara.willa@ten23.health; +41 79 489 39 05

3i Group: Kathryn van der Kroft, Kathryn.VanDerKroft@3i.com; +44 20 7975 3021